CCR2 antagonist monoclonal antibody

This page covers all CCR2 antagonist monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CCR2.

Targets

CCR2

Phase 2 pipeline (1)

• BTT1023 · Biotie Therapies Corp. · Immunology
  BTT1023 is a monoclonal antibody that blocks the CC chemokine receptor 2 (CCR2) to reduce inflammatory cell recruitment and immune activation.